Our evaluation of NfL, a clinically validated biomarker of neurodegeneration, revealed a significant signature of this biomarker in the plasma of 5XFAD/Rubicon KO mice, consistent with what is often observed in neurodegenerative diseases including in human AD patients (Quiroz et al.70). This evidence concerns the gene NEFL and Alzheimer disease.